The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.
As of the end of November 2022 we identify the following current VC trends in Europe:
- In 2022, overall Life Sciences funding has reached EUR 9,182m so far
- Top 5 Deals exceed EUR 140m each, largest transaction amounted to EUR 500m in Doctolib (France)
- Bpifrance (France) dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
- Biotech received 44% of the total investment volume, (no change compared to the previous month)
- Oncology still dominates as the top indication in Biotechnology
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Biotech Venture Capital Monitor – USA 11/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 11/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Venture capital funding in 2022 significantly decreased compared to 2021
The ever-increasing venture capital funding for European life sciences companies halted in 2022. With a roughly EUR 9.6bn volume, the overall financing for European life sciences companies in 2022 decreased significantly compared to 2021 (EUR
Life Sciences Venture Capital Monitor – Europe 11/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 11/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
FCF Biotech Venture Capital Monitor – USA 10/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 10/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Life Sciences Venture Capital Monitor – Europe 10/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 10/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
